Partial response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic BRAF V600EMT colon cancer patient with acquired C-MET amplification and TPM4-ALK fusion: a case reportYingying Huang, Zhongkang Li, Yunbo Zhao et al.|AME Case Reports|2024Cited by 2
Could less apatnib be better? an exploration study of dose-effect of apatnib in 41 stage IV solid tumors.Yingying Huang, Lin Li, Yunbo Zhao et al.|Journal of Clinical Oncology|2018Cited by 0
Clinical characteristics and prognosis of digestive system tumors in elderly patients complicated with acute pulmonary thromboembolismZhixin Bie, Lin Li, Hui Wang et al.|Zhonghua laonian yixue zazhi|2018Cited by 0
Response to crizotinib + regorafenib + PD-1 inhibitor in a metastatic BRAF V600E MT colon cancer patients with acquired C-MET amplification and TPM4- ALK fusion: case report and review of literatureShuai Zhang, Yingying Huang, Xueqing Hu et al.|Research Square|2022Cited by 0
Define a good prognosis of RNF43 codon 659-mutated and concomitant genomic signatures in CRC: an analysis of the cBioPortal databaseFeng Wang, Yingying Huang, Liang‐In Lin et al.|Frontiers in Oncology|2025Cited by 0